Scholar Rock's Credibility Takes a Hit After Management Botched FDA Details — Can Investors Trust the Story Now?

Shares of Scholar Rock plunged 10% to $46.64 on September 15, extending a bruising two-day slide that has erased roughly 19% of the stock's value since September 10, after the company was forced to correct management statements about post-marketing safety requirements tied to its newly approved drug for spinal muscular atrophy. Scholar Rock's Credibility Gap: Can a $310,000-a-Year Drug Survive a Management Misstep on Safety Commitments

Shares of Scholar Rock cratered 10% to $46.64 on September 15, extending a punishing two-day rout after the company was forced to correct its own CEO's statements about FDA-mandated safety obligations tied to its only approved drug — a muscle-targeted treatment for spinal muscular atrophy priced at $310,000 per year.

• Management Said There Were No Safety Requirements — The FDA Label Says Otherwise. Researchers found an increased risk of fractures in patients given the drug, and the FDA's approval noted it may harm a developing fetus and affect reproductive function. During a September 14 investor call, management incorrectly told analysts that no bone or reproductive-safety post-marketing commitments applied. The FDA actually requires a pregnancy-safety study and 15-day fracture alert reports. For a company just transitioning from clinical-stage to commercial drugmaker, getting your own label's obligations wrong on your first investor call is a serious unforced error that raises questions about internal controls and commercial readiness.

• A Key Wall Street Backer Just Stepped to the Sidelines. Barclays downgraded Scholar Rock to Equalweight from Overweight and raised its price target to $58 from $55 following the approval.

The firm said future upside "increasingly depends on commercial execution beyond expectations and pipeline expansion beyond spinal muscular atrophy." Translation: at current prices, the easy money from the FDA approval has been made, and the stock needs flawless execution to go higher — a tougher argument to make when management is stumbling out of the gate.

• The Fracture Signal Could Complicate the Sales Pitch. Fractures occurred in 9% of patients treated with the drug at the approved dose versus 2% on placebo. Mandatory 15-day fracture reporting means every new bone break becomes a visible data point for regulators, prescribers, and short sellers. Short interest already sat at roughly 18 million shares as of late August , giving bears ammunition to pressure the stock on every adverse event report.

• The Broader Bull Case Still Exists — But Execution Risk Just Got Repriced. Across 18 analysts, the average rating remains "Strong Buy" with a 12-month target of $60.75 , implying about 30% upside. Scholar Rock holds roughly $492 million in cash , providing ample runway. The U.S. addressable population is approximately 10,000 SMA patients , and this is the first muscle-directed therapy in the category. But the stock's 19% five-day decline signals the market now demands proof — not promises — that Scholar Rock can launch cleanly while managing real regulatory strings attached to its only product.